Editas Medicine, Inc. (EDIT) community

EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value

$2.14−0.24 (-10.08%)

Close on Nov 12, 2026Market cap $328.66MP/E –Yield –

Community

Notes and questions about Editas Medicine from other investors

No posts about EDIT yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Editas Medicine's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EDIT.

Compare: EDIT vs DTIL · EDIT vs CRSP · EDIT vs SGMOQ · EDIT vs MGX · EDIT vs FDMT

Revenue growth7.4% · median 3159.3%

Operating margin-151.7% · median -291.8%

Net margin-145.0% · median -282.7%

Company	Revenue	Growth
FDMT	$96.06M	+79952.5%
EDIT	$49.83M	+7.4%
DTIL	$45.04M	+6353.0%
SGMOQ	$34.56M	-45.8%
CRSP	$25.17M	-34.3%
MGX	–	–

Company

Next earnings (est.): Mar 8, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 87
Held by institutions: 78.3%
Auditor: Ernst & Young LLP
SEC CIK: 1650664

Advertisement
300 × 250

See a number that looks wrong?